dermavir: emerging a novel topical vaccine for hiv/aids
TRANSCRIPT
![Page 1: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/1.jpg)
Mahesh ShahiB.Pharm, 4th Semester
Crimson College of Technology
DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS
May 2, 2023 Pharmaceutical Seminar - III 1
![Page 2: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/2.jpg)
May 2, 2023 Pharmaceutical Seminar - III
Contents
Quick review about HIV/AIDS
Structure of HIV virus
Life cycle of HIV virus
Treatment
Introduction
Need; No Cure & No Vaccine for HIV
Prophylactic Vs Therapeutic vaccine
Facts
Why Nanomedicine
for vaccination ?
DermaPrep and way
to administration
Clinical trials & its
result
Big challenge
Conclusion
2
![Page 3: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/3.jpg)
May 2, 2023Pharmaceutical Seminar - III
Introduction History
Transmission Symptoms
Treatment
HIV AIDS: Quick Review
3
![Page 4: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/4.jpg)
May 2, 2023Pharmaceutical Seminar - III
Structure of HIV Virus
4
![Page 5: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/5.jpg)
May 2, 2023Pharmaceutical Seminar - III
Life Cycle of HIV Virus
5
![Page 6: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/6.jpg)
May 2, 2023Pharmaceutical Seminar - III
Introduction
6
![Page 7: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/7.jpg)
May 2, 2023Pharmaceutical Seminar - III
Need: No Cure & No Vaccine for HIV
HIV treatment with Drugs: HIV treatment with DermaVir: Minimum 3 drugs - Drug sparing & immune boosting Daily doses - During regular visits (3 months) Systemic toxicities - Transient local toxicities (skin) No full life expectancy (~ 11yr) - Remission (functional cure)
7
![Page 8: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/8.jpg)
May 2, 2023Pharmaceutical Seminar - III
Present & Future VaccineThere is no HIV Vaccine
8
PROPHYLACTIC VACCINEVS
THERAPEUTIC VACCINE
![Page 9: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/9.jpg)
May 2, 2023
Facts
Pharmaceutical Seminar - III9
![Page 10: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/10.jpg)
May 2, 2023
Why do we need nanomedicine for Therapeutic vaccination ?
Scientific reason To target in vivo the antigen to Dendritic cells
Medical reason To provide safe, effective and curative treatment for HIV
Business reason To treat >33 million people
Pharmaceutical Seminar - III10
![Page 11: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/11.jpg)
May 2, 2023
NEW TechnologyDendritic Cell-based Therapeutic Vaccines
Pharmaceutical Seminar - III11
![Page 12: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/12.jpg)
May 2, 2023
“Pathogen-like Nanoparticle” The pDNA and mannosylated polymer self-assemble to form
nanoparticle that1. Structure &2. MoA for targeted pDNA delivery to cells resembles a pathogen
Pharmaceutical Seminar - III12
DermaVir Therapeutic Vaccine Formulation“Pathogen-like Nanoparticles”
The pDNA nanomedicine is filled into a neddle-free applicator ready for delivery with the DermaPrep device
![Page 13: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/13.jpg)
May 2, 2023
Challenge:HIV-1 diversity & genetic diversityObjective: Optimal treatment efficacy in every patientsSolution: DermaVir family with related pDNA covering the
immunological clusters
Pharmaceutical Seminar - III13
Personalized TreatmentOptimal Vaccine for every Patients
DermaPrep & way to administer ???
![Page 14: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/14.jpg)
May 2, 2023
Logistics of DermaVir Therapeutic Vaccination
Pharmaceutical Seminar - III14
![Page 15: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/15.jpg)
May 2, 2023
DermaVir TherapeuticVaccine Administration“DermaPrep”
Pharmaceutical Seminar - III15
Mechanism of Action
![Page 16: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/16.jpg)
May 2, 2023
DermaVir is safe & well toleratedConsistent Preclinical & Clinical Results
Pharmaceutical Seminar - III16
![Page 17: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/17.jpg)
May 2, 2023
DermaVir Boosted Immune System to Fight HIVPhase I/II Clinical Trial Results
GIHU004 study(PI:D, Banhegyi MD,Hungary)- HIV (+VE) subjects on HAART,HIV-RNA <50 copies/ml, CD4> 350/mm3
- 3 subjects/dose; 0.1, 0.4, 0.8mg doses; single DermaVir immunization
Safety Analysis- Single DermaVir treatment was safe and well-tolerated at all doses
Immunogenicity analysis- Antigen-specific memory/precursor T cells are boosted in all subjects
Note: Highest immunogenicity – 0.4 mg DermaVir (4 DermaPrep)
Pharmaceutical Seminar - III17
![Page 18: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/18.jpg)
Contd…
May 2, 2023 18Pharmaceutical Seminar - III
![Page 19: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/19.jpg)
May 2, 2023
Another BIG Challenge ???
Pharmaceutical Seminar - III19
ART???
![Page 20: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/20.jpg)
May 2, 2023
Reasons for Possible !!!
Effectiveness based upon boosted natural immunity
Delayed disease progression
No interference with current or future drug-treatment options
No systemic toxicities
Infrequent administration of a patch (only for three hours)
during regular office visits
No fear of the side effects and acquiring resistance of anti-HIV
drugs
Pharmaceutical Seminar - III20
![Page 21: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/21.jpg)
May 2, 2023
DermaVir Immune Boosting to Fight HIVAntiretroviral sparing Therapeutic Vaccine
Pharmaceutical Seminar - III21
![Page 22: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/22.jpg)
May 2, 2023
DermaVir Immune IntenficationTestable Hypothesis: DermaVir Superiority to HARRT
Pharmaceutical Seminar - III22
URL : journals.plos.org/plosone/article?id=10.1371/journal.pone.0035416
![Page 23: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/23.jpg)
May 2, 2023
Contd…
Pharmaceutical Seminar - III23
![Page 24: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/24.jpg)
May 2, 2023
Conclusion
Pharmaceutical Seminar - III24
Prevention Is Better
Than Cure !!! –no way…
![Page 25: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/25.jpg)
May 2, 2023
References Tripathi KD (2008) Essential Medical Pharmacology (6th Ed.), Jaypee Brothers
Publishers Private Limited, New Delhi, India, pp (770-776).
Katzung BG (2007) Basic and Clinical Pharmcology (10th Ed.), McGraw-Hill Medical, New
York, USA, pp (798-811).
URL : http://www.geneticimmunity.com/dermavir.html (Assessed on: November 9, 2016).
URL : https://www.ncbi.nlm.nih.gov/pubmed/24169 (Assessed on: November 15, 2016).
URL : journals.plos.org/plosone/article?id=10.1371/journal.pone.0035416 (Assessed on:
November 16, 2016).
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157563/ (Assessed on: November 20,
2016).
Pharmaceutical Seminar - III25
![Page 26: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/26.jpg)
May 2, 2023
Presented by;MAHESH SHAHIPharmaceutical Seminar - III
26
![Page 27: DermaVir: Emerging A Novel Topical Vaccine For HIV/AIDS](https://reader035.vdocuments.us/reader035/viewer/2022070521/58f0726e1a28ab235d8b4583/html5/thumbnails/27.jpg)
May 2, 2023Pharmaceutical Seminar - III
27